您要查找的是不是：
- The name is soluble f-m-s-like tyrosine kinase one? 這種蛋白質(zhì)叫做可溶解fms樣酪氨酸激酶一，
- Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer? PDGF受體酪氨酸激酶抑制劑在胰腺癌中是否有作用?
- The inhibitor of VEGF receptor tyrosine kinase was introduced in detail. 詳細介紹了VEGF受體酪氨酸激酶抑制劑的研究進(jìn)展。
- Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. 蘇尼替尼是一種新型的多靶點(diǎn)酪氨酸激酶抑制劑。
- The ABL gene encodes a tyrosine kinase whose activity is tightly regulated. ABL基因編碼一種活性受到嚴格調控的酪氨酸激酶。
- FGFR3, a member of polypeptide growth factor family, is a tyrosine kinase receptor. FGFR3是這一多肽類(lèi)生長(cháng)因子的家族成員之一，它是一種酪氨酸激酶受體。
- The progress in tyrosine kinase inhibitor has been reviewed, including the chemical structures and the pharmacophore models. 本文綜述了近年來(lái)酪氨酸激酶抑制劑的研究進(jìn)展，包括抑制劑的結構和與激酶作用的藥效團模型。
- Isoflavone. Inhibitor of EGFR tyrosine kinase, blocking phosphatidylinositol turnover. 異黃酮類(lèi)。抑制EGFR酪氨酸激酶。阻斷磷脂酰肌糖的翻轉。
- STI571 could induce leukemia cells of ANLL into terminal differentiation by inhibiting c-kit tyrosine kinase. STI571對急性非淋巴細胞白血病原代細胞有誘導向同系終末分化的作用,對c-kit酪氨酸激酶有明顯的抑制作用,且與藥物濃度相關(guān)。
- Objective:To explore the mutation of receptor tyrosine kinase ( RET ) gene in sporadic medullary thyroid carcinoma. 目的:研究散發(fā)型甲狀腺髓樣癌酪氨酸激酶受體基因(RET)的突變情況。
- OBJECTIVE:To discuss the progress and the clinical application evaluation of protein tyrosine kinase(PTK) inhibitors. 目的:探討酪氨酸激酶抑制劑的進(jìn)展與臨床應用評價(jià)。
- The structures and functions of EGFR as well as current status of EGFR tyrosine kinase inhibitors are reviewed. 綜述了EGFR的結構和作用以及近年來(lái)EGFR酪氨酸激酶抑制劑的研究進(jìn)展。
- Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor. 曲妥單抗是一種直接針對HER2酪氨酸激酶受體的單抗。
- We got 10 phage clones which could bind with wild-type and mutant Bcr/Abl tyrosine kinase domain. （2）用菌體呈現隨機7肽庫對構建表達的激酶域蛋白進(jìn)行了生物淘篩，得到了10個(gè)與兩種類(lèi)型激酶域均能結合的共用型噬菌體克隆。
- Gefitinib, the first EGFR tyrosine kinase inhibitor put into clinical trial, was put into market in Japan in 2002. 吉非替尼是EGFR酪氨酸激酶抑制劑中最早進(jìn)入臨床試驗的口服藥物，2002年首次于日本上市。
- EGFR tyrosine kinase inhibitor is an investigative hot spot in targeted therapy of non-small cell lung cancer (NSCLC). 摘要EGFR靶向抑制劑，是目前NSCLC靶向治療的研究熱點(diǎn)之一。
- Angiopoietin acts on Tie-2,which is a receptor tyrosine kinase specifically expressed on endothelial cells. 作用于內皮特異受體酪氨酸激酶酪氨酸激酶受體2。
- Recently, novel antineoplastics were developed by preferentially targeting inhibition of such EGFR tyrosine kinase. 近年來(lái),許多以此為靶點(diǎn)的新抗腫瘤藥物陸續被開(kāi)發(fā),在多種腫瘤治療中取得了令人鼓舞的療效。
- Genistein, the tyrosine kinase inhibitors, plays the effect by an inhibiton of tyrosine phosphorlation. Genistein是酪氨酸激酶的非特異性抑制劑，通過(guò)抑制酪氨酸的磷酸化而發(fā)揮作用。
